Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich’s Ataxia Patient iPSC-Derived Neural Stem Cells

[Image: see text] Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich’s ataxia (FRDA) and Huntington’s disease (HD). While it is clear that HDAC3 is one of the important targets of the 2-aminobenzam...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Bing, Xu, Chunping, Zhang, Yaoyang, Xu, Tao, Gottesfeld, Joel M., Yates, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227551/
https://www.ncbi.nlm.nih.gov/pubmed/24933366
http://dx.doi.org/10.1021/pr500514r

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227551/
https://www.ncbi.nlm.nih.gov/pubmed/24933366
http://dx.doi.org/10.1021/pr500514r

Ejemplares similares